Inventor
WANG JOANNE
US41 patents
⚠️ This page may combine multiple inventors who share the name “WANG JOANNE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
SAMSARA INC
13 patentsUS11756351B1Sep 12, 2023
Vehicle gateway device and interactive cohort graphical user interfaces associated therewith
SAMSARA INC42 citations97
US11365980B1Jun 21, 2022
Vehicle gateway device and interactive map graphical user interfaces associated therewith
SAMSARA INC66 citations97
US11132853B1Sep 28, 2021
Vehicle gateway device and interactive cohort graphical user interfaces associated therewith
SAMSARA INC88 citations97
US11756346B1Sep 12, 2023
Fleet metrics analytics reporting system
SAMSARA INC44 citations96
US12140445B1Nov 12, 2024
Vehicle gateway device and interactive map graphical user interfaces associated therewith
SAMSARA INC21 citations94
US11868919B1Jan 9, 2024
Coverage map for asset tracking
SAMSARA INC35 citations90
US11748377B1Sep 5, 2023
Asset gateway service with cloning capabilities
SAMSARA INC36 citations90
US12172653B1Dec 24, 2024
Vehicle gateway device and interactive cohort graphical user interfaces associated therewith
SAMSARA INC13 citations85
US11488422B1Nov 1, 2022
Fleet metrics analytics reporting system
SAMSARA INC6 citations84
US12118831B1Oct 15, 2024
Fleet metrics analytics reporting system
SAMSARA INC1 citations71
US12488634B1Dec 2, 2025
Fleet metrics analytics reporting system
SAMSARA INC0 citations61
US12182166B1Dec 31, 2024
Asset gateway service with cloning capabilities
SAMSARA INC0 citations59
US12229719B1Feb 18, 2025
Coverage map for asset tracking
SAMSARA INC0 citations58
ZHU HONG
13 patentsUS8455247B2Jun 4, 2013
Cells useful for immuno-based botulinum toxin serotype A activity assays
ZHU HONG10 citations92
US8455213B2Jun 4, 2013
Cells useful for immuno-based botulinum toxin serotype A activity assays
ZHU HONG14 citations92
US9625447B2Apr 18, 2017
Cells useful for immuno-based botulinum toxin serotype A activity assays
ZHU HONG2 citations83
US8691566B1Apr 8, 2014
Cells useful for immuno-based botulinum toxin serotype a activity assays
ZHU HONG4 citations83
US8507271B2Aug 13, 2013
Cells useful for immuno-based botulinum toxin serotype A activity assays
ZHU HONG6 citations83
US8501469B2Aug 6, 2013
Cells useful for immuno-based botulinum toxin serotype A activity assays
ZHU HONG6 citations83
US8476068B2Jul 2, 2013
Cells useful for immuno-based botulinum toxin serotype A activity assays
ZHU HONG3 citations73
US8455248B2Jun 4, 2013
Cells useful for immuno-based Botulinum toxin serotype A activity assays
ZHU HONG4 citations73
US8663982B2Mar 4, 2014
Cells useful for immuno-based botulinum toxin serotype A activity assays
ZHU HONG0 citations62
US8663983B2Mar 4, 2014
Cells useful for immuno-based botulinum toxin serotype A activity assays
ZHU HONG0 citations62
US8603813B2Dec 10, 2013
Cells useful for immuno-based botulinum toxin serotype A activity assays
ZHU HONG0 citations62
US8603812B2Dec 10, 2013
Cells useful for immuno-based botulinum toxin serotype A activity assays
ZHU HONG0 citations62
US8476069B2Jul 2, 2013
Cells useful for immuno-based botulinum toxin serotype A activity assays
ZHU HONG1 citations62
ALLERGAN INC
9 patentsUS8361789B2Jan 29, 2013
Cells useful for immuno-based Botulinum toxin serotype A activity assays
ALLERGAN INC13 citations92
US11332518B2May 17, 2022
Immuno-based botulinum toxin serotype A activity assays
ALLERGAN INC7 citations84
US11261240B2Mar 1, 2022
Immuno-based botulinum toxin serotype A activity assays
ALLERGAN INC7 citations83
US10703806B2Jul 7, 2020
Immuno-based botulinum toxin serotype A activity assays
ALLERGAN INC10 citations81
US10900967B2Jan 26, 2021
Immuno-based retargeted endopeptidase activity assays
ALLERGAN INC2 citations72
US10345306B2Jul 9, 2019
Immuno-based retargeted endopeptidase activity assays
ALLERGAN INC4 citations72
US9651553B2May 16, 2017
Immuno-based retargeted endopeptidase activity assays
ALLERGAN INC3 citations72
US10451621B2Oct 22, 2019
Highly sensitive cell-based assay to detect the presence of active botulinum neurotoxin serotype-A
ALLERGAN INC3 citations68
US10912823B2Feb 9, 2021
Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin
ALLERGAN INC0 citations56